1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,280 | 6,440 | 14:28 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SELVITA Aktie jetzt für 0€ handeln | |||||
| 21.05. | Selvita S.A.: Selvita reports Q1 2026 results and launches strategic options review | 255 | PR Newswire | KRAKÓW, Poland, May 21, 2026 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading Drug Discovery and Development organizations in Europe, has published its... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 278,00 | -0,57 % | Stryker fully launches Mako robotic power system for knee surgery in US | ||
| PALATIN TECHNOLOGIES | 8,620 | +0,23 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| VIKING THERAPEUTICS | 31,900 | 0,00 % | Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 | ||
| COSCIENS BIOPHARMA | 4,810 | -1,43 % | COSCIENS Biopharma Inc. Completes Share Capital Amendment | TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), today announced the previously announced consolidation (the "Consolidation")... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 67,90 | +0,53 % | Halozyme Partners Incyte To Devolop Subcutaneous Formulations Of INCA033989 Using ENHANZE Technology | WASHINGTON (dpa-AFX) - Biopharmaceutical company Halozyme Therapeutics, Inc. (HALO) announced Monday that it has entered into a global collaboration and license agreement with Incyte Corp. (INCY)... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 5,130 | +0,98 % | AbCellera-Aktie nach Rücksetzer mit +250% Potenzial? | Die AbCellera-Aktie hat nach ihrer starken Aufwärtsbewegung zuletzt eine gesunde Korrektur eingelegt und damit einen Teil der vorherigen Gewinne abgegeben. Nun richtet sich der Blick der Anleger erneut... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 263,40 | -0,45 % | ROUNDUP/'WSJ': US-Investor Elliot steigt bei Sartorius-Großaktionär Bio-Rad ein | NEW YORK (dpa-AFX) - Der US-Investor Elliott hat laut einem Medienbericht eine beachtliche Beteiligung an dem Sartorius-Großaktionär Bio-Rad Laboratories aufgebaut. Der aktivistische Investor wolle... ► Artikel lesen | |
| GLOW LIFETECH | 0,018 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Advances National Expansion Strategy with Quebec Commercial Partnership | Toronto, Ontario--(Newsfile Corp. - July 13, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce it has entered into an exclusive Quebec... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 2,220 | -2,63 % | BioLineRx Ltd.; Hemispherian AS: BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model | Synergy was demonstrated in a combination arm of GLIX1 and the PARP inhibitor olaparib at low doses, with substantially better efficacy compared to the control arm and compared to each... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| MINERVA NEUROSCIENCES | 3,742 | +3,20 % | Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs | Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,240 | -2,99 % | Akari Therapeutics Plc: Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics | TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,080 | +2,97 % | B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target | ||
| COCRYSTAL | 0,790 | -1,86 % | Cocrystal Pharma, Inc. - 8-K, Current Report |
SELVITA SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -6,04 % bei einem Aktienkurs von 6,220 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SELVITA SA finden Sie auf Wallstreet Online.